Thursday, October 11, 2012
Immunovaccine Inc., of Halifax, Nova Scotia, reported interim results from its Phase I trial of DPX-Survivac, an ovarian cancer vaccine, showing that, to date, all nine patients receiving the vaccine in combination with low-dose oral cyclophosphamide produced a targeted immune response following only one or two vaccine administrations.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.